within Pharmacolibrary.Drugs.ATC.G;

model G02CB03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.63,
    Cl             = 6e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.173,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00135,
    Tlag           = 2640,            
    Vdp             = 0.869,
    k12             = 12.0,
    k21             = 12.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cabergoline is a long-acting dopamine D2 receptor agonist used primarily for the treatment of hyperprolactinemia and disorders associated with prolactin excess. It is also sometimes used off-label for Parkinson's disease. Cabergoline is approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers of both sexes after oral administration.</p><h4>References</h4><ol><li><p>Del Dotto, P, &amp; Bonuccelli, U (2003). Clinical pharmacokinetics of cabergoline. <i>Clinical pharmacokinetics</i> 42(7) 633–645. DOI:<a href=\"https://doi.org/10.2165/00003088-200342070-00003\">10.2165/00003088-200342070-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12844325/\">https://pubmed.ncbi.nlm.nih.gov/12844325</a></p></li><li><p>Nakatsuka, A, et al., &amp; Nomoto, M (2006). Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson&#x27;s disease. <i>Journal of pharmacological sciences</i> 100(1) 59–64. DOI:<a href=\"https://doi.org/10.1254/jphs.fp0050711\">10.1254/jphs.fp0050711</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16410677/\">https://pubmed.ncbi.nlm.nih.gov/16410677</a></p></li><li><p>Andreotti, AC, et al., &amp; Pontiroli, AE (1995). Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. <i>The Journal of clinical endocrinology and metabolism</i> 80(3) 841–845. DOI:<a href=\"https://doi.org/10.1210/jcem.80.3.7883840\">10.1210/jcem.80.3.7883840</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7883840/\">https://pubmed.ncbi.nlm.nih.gov/7883840</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CB03;
